Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, shared Agenus’s post on LinkedIn, adding:
“The most meaningful advances come from asking bigger questions-not just whether a therapy works, but whether it can change the course of disease.
Congratulations to Agenus on today’s announcement supporting the Phase 3 ROBBIN trial in high-risk MSS colon cancer. Built on the precedent trials in this setting (NEST and UNICORN), ROBBIN will evaluate whether moving immunotherapy before surgery can improve outcomes for patients.
The presentations from Prof. Myriam Chalabi, Pashtoon Kasi, and Steven O’Day offered an outstanding perspective on why this question matters for patients and for the future of early immuno-oncology.”
Quoting Agenus’s post:
“Agenus announced an oversubscribed private placement of up to $340M to advance ROBBIN, its planned registrational Phase 3 trial of neoadjuvant BOT+BAL in high-risk Stage II/III MSS colon cancer.
The financing includes $85M upfront and up to $255M upon warrant exercise.
- Read the full release
- Join 8:30 a.m ET webcast: Passcode: 460308.”
You can also read:
